NIVO/IPI Combo Demonstrates Long-Term Efficacy in NSCLC

After 6 years, previous tumor response, tumor burden reduction, and baseline health-related quality of life all correlated with overall survival.

Related Keywords

Texas ,United States ,Bristol Myers Sqiubb ,Calithera Biosciences ,Solange Peters ,Lausanne Switzerland University Hospital ,National Center ,Guardant Health ,Pfizer ,Bristol Myers Squibb ,Boehringer Ingelheim ,Novartis ,Amgen ,University Of Texas Md Anderson Cancer Center ,World Conference ,Ferdinandos Skoulidis ,Biotechnology Information ,Bristol Myers ,Tango Therapeutics ,Mirati Therapeutics ,Lung Cancer ,Ung Carcinoma ,Ancer Lung ,Chemotherapy ,Non Small Cell Lung Cancer ,Nsclc ,Tumor ,Biologic Therapy ,Small Cell Lung Cancer ,Quality Of Life ,Pol ,Ealth Related Quality Of Life ,Rqol ,Cancer ,Alignant Neoplasia ,Arcinoma ,Immunotherapy ,Lung ,Histology ,